Gain Therapeutics, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | — | — | $55,180 | $140,108 | $164,994 |
| Research and development | $10.2M | $10.8M | $11.5M | $8.4M | $7.2M |
| Operating expenses | $18.7M | $20.4M | $22.3M | $17.9M | $14.0M |
| Operating income | -$18.7M | -$20.4M | -$22.3M | -$17.8M | -$13.8M |
| Pretax income | -$19.3M | -$19.9M | -$22.2M | -$17.5M | -$13.9M |
| Income tax expense | $861,118 | $536,815 | $79,275 | $92,976 | $4,008 |
| Net income | -$20.2M | -$20.4M | -$22.3M | -$17.6M | -$13.9M |
| Balance Sheet | |||||
| Cash and equivalents | $20.8M | $10.4M | $11.8M | $7.3M | $36.9M |
| Current assets | $22.2M | $11.6M | $17.8M | $21.1M | $37.7M |
| Total assets | $22.8M | $12.1M | $18.6M | $24.1M | $39.0M |
| Current liabilities | $3.4M | $3.9M | $4.9M | $4.1M | $2.6M |
| Total liabilities | $4.3M | $4.8M | $6.0M | $5.2M | $4.2M |
| Stockholders' equity | $18.6M | $7.3M | $12.6M | $18.9M | $34.8M |
| Cash Flow Statement | |||||
| Cash from operations | -$18.5M | -$18.9M | -$18.9M | -$14.7M | -$12.4M |
| Depreciation and amortization | $94,046 | $84,071 | $83,579 | $64,168 | $15,484 |
| Stock-based compensation | $1.8M | $2.4M | $3.3M | $1.5M | $839,371 |
| Capital expenditure | — | $22,493 | $15,358 | $118,953 | $94,212 |
| Free cash flow | — | -$18.9M | -$18.9M | -$14.8M | -$12.5M |
| Impairments | $0 | $0 | $0 | $0 | $0 |
Shares outstanding 42.7M · Free float 95.8%
Annual filing data through FY ended December 31, 2025; float as of July 15, 2026.